Here are three things to know:
1. The funds will be used for the development and synthesis of a potential bone graft substitute product focused on bone regeneration in spinal fusion procedures.
2. The lead product, Nell-1, has shown clinical potential in the laboratory and in animal testing.
3. The funding round included Musculoskeletal Transplant Foundation, Orthofix and Hankey Capital.
More articles on devices:
Stryker’s net earnings up 79.5%; Orthopedics sales reach $1.1B: 9 key notes on Q1 2016
FDA clears Exatech’s Vantage Total Ankle — 5 highlights
Medtech’s ROSA system to be featured at AANS annual meeting — 3 quick notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
